Introduction
Serotonin (5 Hydroxytryptamine, 5 Ht) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Mermaid diagram (expand to render)
Serotonin, also known as 5-hydroxytryptamine (5-HT), is a monoamine neurotransmitter derived from the amino acid tryptophan that modulates a vast array of physiological and behavioral processes, including mood, cognition, sleep, appetite, pain perception, and neuroendocrine function. In the central nervous system, serotonergic [neurons](/entities/neurons) are concentrated in the raphe nuclei of the brainstem, from which they project diffusely throughout the brain, including the [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), [basal-ganglia](/brain-regions/basal-ganglia), [thalamus](/brain-regions/thalamus), and [cerebellum](/brain-regions/cerebellum) [@lanciego2025]. [@zhang2025]
Serotonergic dysfunction is a prominent feature of multiple [neurodegenerative diseases. In [alzheimers](/diseases/alzheimers-disease), early degeneration of the raphe nuclei and depletion of serotonin contribute to depression, sleep disturbances, circadian disruption, and cognitive decline. In [parkinsons](/diseases/parkinsons-disease), serotonergic pathology is implicated in non-motor symptoms including depression, anxiety, psychosis, and levodopa-induced dyskinesias. Emerging evidence positions the serotonergic system as a promising therapeutic target across neurodegenerative conditions [@zhang2025]. [@meltzer1998]
Biosynthetic Pathway
Serotonin is synthesized from the essential amino acid L-tryptophan through a two-step enzymatic process: [@ohno2011]
Tryptophan hydroxylase (TPH): Converts L-tryptophan to 5-hydroxytryptophan (5-HTP). Two isoforms exist: TPH1 (peripheral, gut and pineal gland) and TPH2 (central, raphe nuclei). TPH2 is the rate-limiting enzyme for brain serotonin synthesis and requires tetrahydrobiopterin (BH4) and molecular oxygen as cofactors.
Aromatic L-amino acid decarboxylase (AADC): Converts 5-HTP to serotonin (5-HT). This is the same enzyme involved in [dopamine](/entities/dopamine) synthesis, requiring pyridoxal phosphate (vitamin B6) as a cofactor.Notably, serotonin does not cross the [blood-brain-barrier](/entities/blood-brain-barrier), so CNS and peripheral serotonin pools are functionally independent. Approximately 95% of total body serotonin resides in the gastrointestinal tract, where it is produced by enterochromaffin cells—a connection highly relevant to [gut-brain-axis](/entities/gut-brain-axis) signaling in neurodegeneration. [@barnes2007]
Vesicular Transport and Release
After synthesis, serotonin is transported into synaptic vesicles by vesicular monoamine transporter 2 (VMAT2/SLC18A2). Upon neuronal depolarization, 5-HT is released into the synaptic cleft by calcium-dependent exocytosis. [@codony2011]
Reuptake and Degradation
Serotonin signaling is terminated primarily by the serotonin transporter (SERT/SLC6A4), which mediates reuptake of 5-HT from the synaptic cleft into the presynaptic terminal. SERT is the principal target of selective serotonin reuptake inhibitors (SSRIs), the most widely prescribed class of antidepressants. [@chowdhury2024]
Intracellular serotonin is degraded by monoamine oxidase A (MAO-A) to 5-hydroxyindoleacetaldehyde, which is further oxidized by aldehyde dehydrogenase to 5-hydroxyindoleacetic acid (5-HIAA), the primary serotonin metabolite. 5-HIAA levels in cerebrospinal fluid (CSF) serve as a biomarker of central serotonergic activity and are consistently reduced in [alzheimers](/diseases/alzheimers-disease) patients [@meltzer1998]. [@li2024]
Melatonin Pathway
In the pineal gland, serotonin serves as the precursor for melatonin synthesis through sequential N-acetylation (by AANAT) and O-methylation (by ASMT). This serotonin-melatonin pathway is critical for circadian rhythm regulation and is severely disrupted in AD, contributing to sundowning behavior and sleep-wake cycle disturbances. [@carta2017]
Serotonin Receptors
The serotonin receptor system is the most complex of any neurotransmitter, comprising 7 families (5-HT1 to 5-HT7) and at least 14 receptor subtypes. All are G protein-coupled receptors except 5-HT3, which is a ligand-gated ion channel. [@duan2024]
5-HT1 Family (Gi/Go-coupled, inhibitory)
- 5-HT1A: Expressed as somatodendritic autoreceptors on raphe [neurons](/entities/neurons) (inhibiting serotonin release) and as postsynaptic receptors in [hippocampus](/brain-regions/hippocampus), [cortex](/brain-regions/cortex), and amygdala. 5-HT1A receptor density is reduced in AD brains, correlating with cognitive decline and neurofibrillary tangle burden. 5-HT1A agonists (buspirone, tandospirone) show potential for treating behavioral symptoms in AD and motor complications in PD [@ohno2011].
- 5-HT1B/1D: Primarily presynaptic autoreceptors/heteroreceptors regulating neurotransmitter release. Targets of triptan antimigraine drugs.
5-HT2 Family (Gq-coupled, excitatory)
- 5-HT2A: Highly expressed in cortical pyramidal [neurons](/entities/neurons); mediates psychedelic effects and is the target of atypical antipsychotics (risperidone, quetiapine). 5-HT2A receptor density is reduced in AD temporal and frontal [cortex](/brain-regions/cortex). Pimavanserin, a selective 5-HT2A inverse agonist, is approved for [parkinsons](/diseases/parkinsons-disease) psychosis and is being investigated for AD psychosis [@barnes2007].
- 5-HT2C: Expressed in the choroid plexus and limbic structures; regulates appetite, mood, and CSF production. Relevant to weight changes in neurodegenerative disease.
5-HT3 (Ligand-gated cation channel)
The only ionotropic serotonin receptor; mediates fast excitatory neurotransmission. Expressed on GABAergic interneurons and vagus nerve afferents. 5-HT3 antagonists (ondansetron) have shown modest procognitive effects in preclinical AD models. [@rodrguez2012]
5-HT4 (Gs-coupled, excitatory)
Expressed in [hippocampus](/brain-regions/hippocampus), [cortex](/brain-regions/cortex), and gastrointestinal tract. 5-HT4 receptor activation promotes non-amyloidogenic processing of [app](/genes/app) [@politis2015]
Expressed exclusively in the CNS, primarily in striatum, [hippocampus](/brain-regions/hippocampus), and [cortex](/brain-regions/cortex). 5-HT6 receptor antagonists (idalopirdine, intepirdine) enhance [acetylcholine](/entities/acetylcholine), [glutamate](/entities/glutamate), and [dopamine](/entities/dopamine) release and have been extensively investigated as cognitive enhancers in AD. Despite promising preclinical data, Phase III clinical trials have not met primary endpoints, though the pharmacological rationale remains sound [@codony2011]. [@dopamine]
5-HT7 (Gs-coupled, excitatory)
Involved in circadian rhythm regulation, thermoregulation, and memory. Expressed in [hippocampus](/brain-regions/hippocampus), [thalamus](/brain-regions/thalamus), and hypothalamus. 5-HT7 receptor modulation may address circadian disturbances in AD. [@norepinephrine]
Role in Neurodegenerative Diseases
Alzheimer's Disease
Serotonergic dysfunction is a consistent finding in AD, with multiple lines of evidence: [@acetylcholine]
Raphe Nuclei Degeneration: The dorsal and median raphe nuclei show neuronal loss and tau] pathology early in AD progression (Braak stages I–II), even before neocortical involvement. This produces widespread serotonin depletion across cortical and subcortical targets [@lanciego2025].
Reduced Serotonin and Metabolites: Postmortem AD brains show 40–70% reductions in serotonin and 5-HIAA levels in [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), and CSF. SERT binding is also reduced, reflecting loss of serotonergic terminals.
Circadian and Glymphatic Disruption: Serotonin depletion impairs circadian rhythm regulation and the [glymphatic-system](/entities/glymphatic-system), reducing [amyloid-beta](/proteins/amyloid-beta) clearance during sleep and potentially accelerating disease progression [@zhang2025].
Amyloid Interaction: Serotonin signaling through 5-HT4 receptors promotes non-amyloidogenic [app](/genes/app)**: Surviving serotonergic terminals aberrantly convert levodopa to [dopamine](/entities/dopamine) and release it without proper feedback regulation, producing pulsatile dopamine surges that cause dyskinesias [@carta2017].
- Psychosis: 5-HT2A receptor upregulation in [cortex](/brain-regions/cortex) contributes to visual hallucinations; pimavanserin targets this mechanism.
- Sleep Disturbances: REM sleep behavior disorder and excessive daytime sleepiness linked to raphe nuclei degeneration.
- Cognitive Decline: Serotonergic denervation contributes to executive dysfunction and dementia in PD.
Amyotrophic Lateral Sclerosis
Emerging evidence links serotonergic dysfunction to [als](/diseases/amyotrophic-lateral-sclerosis): [@neurotransmitters]
- Reduced 5-HT levels in the spinal cord of ALS patients
- Serotonergic modulation of motor neuron excitability
- 5-HT2B/2C receptor involvement in spasticity
- Potential role in pseudobulbar affect (pathological crying/laughing)
Frontotemporal Dementia
[ftd](/diseases/frontotemporal-dementia) patients show serotonergic deficits contributing to behavioral disinhibition, apathy, dietary changes, and compulsive behaviors. SSRI treatment is first-line pharmacotherapy for behavioral symptoms of FTD. [@parkinsons]
Therapeutic Approaches
Current Serotonergic Therapies in Neurodegeneration
- SSRIs (escitalopram, citalopram, fluoxetine, sertraline): First-line for depression in AD and PD; citalopram has shown modest efficacy for agitation in AD (CitAD trial). SSRIs also reduce [amyloid-beta](/proteins/amyloid-beta) production in preclinical models [@zhang2025].
- Pimavanserin (Nuplazid): Selective 5-HT2A inverse agonist approved for PD psychosis; under investigation for AD psychosis.
- Trazodone: 5-HT2A antagonist and serotonin reuptake inhibitor; used for insomnia and agitation in dementia.
- Buspirone: 5-HT1A partial agonist used for anxiety in dementia patients.
Emerging Strategies
5-HT4 receptor agonists: Dual procognitive and anti-amyloid potential; prucalopride and novel compounds in preclinical/early clinical development.
Multimodal serotonergic agents: Vortioxetine (5-HT3/5-HT7 antagonist, 5-HT1B partial agonist, 5-HT1A agonist, SERT inhibitor) shows procognitive effects beyond antidepressant activity.
5-HT6 antagonists: Despite Phase III failures, next-generation 5-HT6 antagonists with improved selectivity continue in development.
Psychedelic-assisted therapy: Psilocybin (5-HT2A agonist) and related compounds are being investigated for depression and existential distress in neurodegenerative disease, with potential neuroprotective effects via [bdnf](/proteins/bdnf) upregulation and neuroplasticity promotion.
Targeting serotonylation: Modulating transglutaminase 2-mediated serotonylation as a novel therapeutic approach.Serotonin as a Biomarker
- CSF 5-HIAA: Reduced in AD and PD; correlates with severity of depressive symptoms and cognitive impairment
- SERT PET imaging: 11CDASB PET reveals serotonergic denervation patterns in AD and PD, predicting depression and cognitive decline
- Platelet serotonin: Peripheral serotonin in platelets (which express SERT) mirrors central serotonergic function; reduced in AD patients
- Tryptophan metabolomics: Altered kynurenine/tryptophan ratio in AD reflects immune-mediated diversion of tryptophan away from serotonin synthesis toward neurotoxic kynurenine metabolites
Background
The study of Serotonin (5 Hydroxytryptamine, 5 Ht) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [@alzheimers]
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [@serotonin]
Brain Atlas Resources
- Allen Human Brain Atlas: [Serotonin expression search](https://human.brain-map.org/microarray/search/show?search_term=Serotonin)
- Allen Mouse Brain Atlas: [Serotonin search](https://mouse.brain-map.org/search/index.html?query=Serotonin)
- Allen Cell Type Atlas: [Transcriptomic cell type reference](https://portal.brain-map.org/atlases-and-data/rnaseq)
- BrainSpan Developmental Transcriptome: [Serotonin developmental expression](https://www.brainspan.org/rnaseq/search/index.html?search_term=Serotonin)
- [Serotonergic [Neurons](/entities/neurons)[/[serotonergic-neurons
- [Serotonin Receptors
- [Depression](/diseases/depression)
- [Neurotransmitter](/genes/ran)
- [Raphe Nuclei](/brain-regions/raphe-nuclei)
- [Mood Disorders
External Links
- [PubMed Search: Serotonin (5-Hydroxytryptamine, 5-HT)](https://pubmed.ncbi.nlm.nih.gov/?term=Serotonin+%285-Hydroxytryptamine%2C+5-HT%29)
- [Google Scholar Search: Serotonin (5-Hydroxytryptamine, 5-HT)](https://scholar.google.com/scholar?q=Serotonin+%285-Hydroxytryptamine%2C+5-HT%29)
Additional evidence sources: [@httlpr] [@serotonina] [@serotonin2018]
References
Lanciego JL, et al. (2025). Serotonergic regulation in, alzheimers. International Journal of Molecular Sciences, 26(11), 5218. [PMC12154332 (2025)
Zhang Y, et al. (2025). Serotonergic regulation in, alzheimers. International Journal of Molecular Sciences, 26(11), 5218. [Full text (2025)
Meltzer CC, et al., (1998). Serotonin in aging, late-life depression, and Alzheimer's Disease: the emerging role of functional imaging. Neuropsychopharmacology, 18(6), 407–430. [Nature (1998)
Ohno Y. (2011). Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and, parkinsons. CNS Neuroscience & Therapeutics, 17(2), 58–65. [Wiley (2011)
Unknown, Barnes NM, Sharp T. (2007). Serotonin 2A (5-HT2A) receptor function. In: Bhatt DK, ed. Serotonin Receptors in Neurobiology. NCBI Bookshelf. [NCBI (2007)
Unknown, Codony X, Vela JM, Ramírez MJ. (2011). 5-HT6 receptor and cognition. Current Opinion in Pharmacology, 11(1), 94–100. [PMC3268149 (2011)
Chowdhury A, et al., (2024). Serotonin enhances neurogenesis biomarkers, hippocampal volumes, and cognitive functions in Alzheimer's Disease. Molecular Brain, 17, 86. [Full text (2024)
Li Y, et al., (2024). Role of serotonylation and SERT posttranslational modifications in Alzheimer's Disease pathogenesis. Aging and Disease. [Full text (2024)
Carta M, Tronci E. (2017). Serotonergic approaches in, parkinsons: translational perspectives, an update. ACS Chemical Neuroscience, 8(5), 973–978. [ACS (2017)
Duan Q, et al., (2024). Targeting 5-HT is a potential therapeutic strategy for neurodegenerative diseases. International Journal of Molecular Sciences, 25(24), 13446. [Full text (2024)
Rodríguez JJ, et al., (2012). Serotonin: a new hope in Alzheimer's Disease? ACS Chemical Neuroscience, 3(9), 635–636. [ACS (2012)
[Unknown, Politis M, Niccolini F. (2015). Serotonin in Parkinson's Disease. Behavioural Brain Research, 277, 136–145. [PubMed (2015)](https://pubmed.ncbi.nlm.nih.gov/24698768/)
Unknown, - dopamine — Another key neurotransmitter affected in Parkinson's Disease (n.d.)
Unknown, - norepinephrine — Noradrenergic system and neurodegeneration (n.d.)
Unknown, - acetylcholine — Cholinergic dysfunction in Alzheimer's Disease (n.d.)
Unknown, - [Neurotransmitters] — Overview of neurotransmitter systems in the brain (n.d.)
Unknown, - parkinsons — Disease where serotoninergic therapies are being explored (n.d.)
Unknown, - alzheimers — Disease with serotonergic system alterations## External Links (n.d.)
-, Serotonin (5-HT) - Wikipedia (n.d.)
-, 5-HTTLPR and Serotonin Transporter - NCBI (n.d.)
-, Serotonin Receptor Pharmacology - IUPHAR/BPS (n.d.)
-, Serotonin in the Brain - BrainFacts.org (2018)Pathway Diagram
The following diagram shows the key molecular relationships involving Serotonin (5-Hydroxytryptamine, 5-HT) discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)